CCL5 and prostate adenocarcinoma: While previous studies in prostate adenocarcinoma [63] have shown that CCL5 upregulates androgen receptor signaling and contributes to enzalutamide resistance—an effect that may be mitigated by maraviroc—our current study focuses on the role of the unique context of cisplatin treatment in NEPC.